✦ LIBER ✦

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia

✍ Scribed by Hiroto Inaba; Clinton F. Stewart; Kristine R. Crews; Shengping Yang; Stanley Pounds; Ching-Hon Pui; Jeffrey E. Rubnitz; Bassem I. Razzouk; Raul C. Ribeiro

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 163 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24712

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of rituximab in combination wit

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia

✍ Monica Else; Nnenna Osuji; Francesco Forconi; Claire Dearden; Ilaria Del Giudice 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

## Abstract ## BACKGROUND. The purine analogs pentostatin and cladribine have revolutionized the treatment of hairy cell leukemia (HCL) with overall responses in greater than 85% of patients and a median progression‐free survival of up to 15 years. They continue to be effective at second‐ and even

Single-dose mitoxantrone in combination

Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia

✍ Sung-Sook Lee; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Se Hyung Kim; Sung-nam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Mitoxantrone, etoposide, and cytarabine

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia : An Eastern Cooperative Oncology Group pilot study

✍ Martin S. Tallman; Sandra Lee; Branimir I. Sikic; Elisabeth Paietta; Peter H. Wi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Background: One potential mechanism of drug resistance to chemotherapy is the overexpression of multidrug resistance (mdr) genes coding for p-glycoprotein (p-gp), which leads to reduced intracellular retention of chemotherapy. this study tested the efficacy and toxicity of mitoxantrone, etoposid

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated

A phase II study of homoharringtonine fo

A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: A pediatric oncology group study

✍ Bell, Beverly A. ;Chang, Myron N. ;Weinstein, Howard J. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract ## Background Homoharringtonine (HHT) is a plant alkaloid that is derived from a Chinese evergreen tree. Its mechanism of action is thought to be by inhibition of protein, DNA, and RNA synthesis by inhibition of chain initiation. The treatment of acute myelogenous leukemia (AML) in chi

A single, high dose of idarubicin combin

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

✍ Mark A. Weiss; Timothy B. Aliff; Martin S. Tallman; Stanley R. Frankel; Matt E. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Background: The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. one option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense